Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBT (2016 - 2025)

KalVista Pharmaceuticals' EBT history spans 11 years, with the latest figure at -$53.0 million for Q2 2025.

  • For Q2 2025, EBT fell 12.98% year-over-year to -$53.0 million; the TTM value through Apr 2025 reached -$184.9 million, down 38.89%, while the annual FY2025 figure was -$91.6 million, 27.64% up from the prior year.
  • EBT for Q2 2025 was -$53.0 million at KalVista Pharmaceuticals, down from -$44.5 million in the prior quarter.
  • Across five years, EBT topped out at -$12.5 million in Q1 2021 and bottomed at -$53.0 million in Q2 2025.
  • The 4-year median for EBT is -$34.7 million (2024), against an average of -$35.4 million.
  • The largest annual shift saw EBT decreased 1.36% in 2021 before it plummeted 53.44% in 2024.
  • A 4-year view of EBT shows it stood at -$12.5 million in 2021, then tumbled by 131.39% to -$29.0 million in 2023, then tumbled by 53.44% to -$44.5 million in 2024, then fell by 19.31% to -$53.0 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's EBT are -$53.0 million (Q2 2025), -$44.5 million (Q4 2024), and -$40.4 million (Q3 2024).